ArticleWorld journal of gastroenterology2005
Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma.
Article in World journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 39 citations in OpenAlex.
- Case Report: Serum AKR1B10 as a complementary marker for the detection of AFP-negative hepatocellular carcinoma - a report of two cases.Frontiers in medicine · 2026Article
- A Mouse Model of Hepatocellular Carcinoma Induced by Streptozotocin and High-Fat Diet.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice.Cell death & disease · 2023Article
- New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma.Frontiers in oncology · 2020Review
- MiR-494-3p promotes PI3K/AKT pathway hyperactivation and human hepatocellular carcinoma progression by targeting PTEN.Scientific reports · 2018Article
- Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma.Biomarkers in cancer · 2016Review
- Pericentral activity of alpha-fetoprotein enhancer 3 and glutamine synthetase upstream enhancer in the adult liver are regulated by β-catenin in mice.Hepatology (Baltimore, Md.) · 2012Article
- The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types.British journal of cancer · 2007Article
- Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2006Article
- Current staging of hepatocellular carcinoma: imaging implications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2006Review
- Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma.Journal of medicine and lifeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo characterize the alpha-fetoprotein (AFP) positive and negative hepatocellular carcinoma (HCC) samples.
methodsThirty-seven paraffin-embedded human HCC samples were analyzed by immunohistochemistry for the following antigens: AFP, beta-catenin, p53, CD44, MSH-2, MLH-1, and HNF-4. The tumors were divided into two groups based on the AFP expression. The immunophenotypic data and important clinical parameters were studied between the two groups.
resultsTwenty-one of the thirty-seven examined HCCs were AFP positive. Seven with nuclear p53 staining were AFP positive, while seven tumors with nuclear beta-catenin staining were AFP negative. CD44 staining and high histological tumor grade were more frequent among the AFP-positive HCCs. The other immunophenotypical and clinical parameters did not show statistically significant difference in their distribution between the AFP positive and negative samples.
conclusionAFP expression in HCC correlates with unfavorable prognostic factors, while nuclear beta-catenin positivity is more common among the AFP-negative liver tumors. This observation supports the microarray data on in vivo human tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.